# Mounjaro (tirzepatide)

Type: Product

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/mounjaro-tirzepatide
Canonical HTML page: https://getlegalbrief.com/entity/mounjaro-tirzepatide

## Timeline

- **2026-07-21**: Lawsuit Filed — Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
- **2026-03**: FDA Approves Wegovy 7.2 mg — Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.

## Recent coverage (1 stories)

### Novo Sues Lilly: Omits Wegovy’s 19% Weight Loss, Seeks Injunction
2026-07-21 14:14:08 · Sentiment: Neutral · Impact: 7/10 · Sources: 3

Novo Nordisk alleges Lanham Act violations; case tests whether outdated comparisons in DTC ads constitute false advertising, with potential precedent for pharma.
Full story: https://getlegalbrief.com/story/novo-sues-lilly-false-advertising-glp1-injunction

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.